Abstract
Objectives This study aimed to investigate the prognostic value of Log odds of positive lymph nodes (LODDS) for predicting the long-term prognosis of patients with node-positive lung neuroendocrine tumors (LNETs).
Materials and Methods We collected 506 eligible patients with resected N1/N2 classification LNETs from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. First, we applied the Cox proportional-hazards regression model to evaluate the relationship between LODDS and study endpoints (cancer-specific survival [CSS] and overall survival [OS]) based on the entire cohort. Second, the study cohort was divided into derivation cohort (n=300) and external validation cohort (n=206) based on different geographic regions. Nomograms were constructed and validated based on these two cohorts to predict the 1-, 3- and 5-year survival of patients with LNETs. The accuracy and clinical practicability of nomograms were tested and compared by Harrell’s concordance index (C-index), integrated discrimination improvement (IDI), net reclassification improvement (NRI), calibration plots, and decision curve analyses.
Results The Cox proportional-hazards model showed the high LODDS group (-0.33≤LODDS≤1.14) had significantly higher mortality compared to those in the low LODDS group (-1.44 ≤LODDS<-0.33) for both CSS and OS. In addition, besides LODDS, age at diagnosis, histotype, type of surgery, radiotherapy, and chemotherapy were shown as independent predictors in Cox regression analyses and included in the nomograms. The values of c-index, NRI, and IDI indicated that the established nomogram performed significantly better than the conventional eighth edition of the TNM staging system alone. The calibration plots for predictions of the 1-, 3-, and 5-year OS were in excellent agreement. Decision curve analyses showed that the nomogram had value in terms of clinical application.
Conclusions We created visualized nomograms for CSS and OS of LNET patients, facilitating clinicians to provide highly individualized risk assessment and therapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Development Fund for the Department of Anesthesiology of Shanghai Pulmonary Hospital. The funders have no role in the study design, data collection, data analysis and completion of the manuscripts.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
- Abbreviations
- LNET
- lung neuroendocrine tumor
- TC
- typical carcinoid
- AC
- atypical carcinoid
- LCNEC
- large cell neuroendocrine carcinoma
- SCLC
- small cell lung carcinoma
- NSCLC
- non-small cell lung cancer
- AJCC
- American Joint Committee on Cancer
- UICC
- Union for International Cancer Control
- TNM
- tumor-node-metastasis
- LN
- lymph node
- NPLN
- number of positive lymph node
- LODDS
- log odds of positive lymph nodes
- SEER
- Surveillance, Epidemiology, and End Results
- NDLN
- number of dissected lymph node
- CSS
- lung cancer-specific survival
- OS
- overall survival
- SD
- standard deviation
- IQR
- interquartile range
- HR
- hazard ratio
- CI
- confidence interval
- PRCDA
- purchased/referred care delivery area
- c-index
- concordance index
- IDI
- integrated discrimination improvement
- NRI
- net reclassification improvement
- DCA
- decision curve analysis
- LNR
- lymph node ratio
- IASLC
- International Association for the Study of Lung Cancer